Any guesses? It's long overdue for a rally but me thinks it possibly might be a milestone material event on the new dosing trial protocol
Finally the sound of reason from what's become an out house pump
Poster presentations always are. No lectures just a bulletin board with bullet points. Joko is making this event out to be the final supper for Incy as Gern eats their lunch, which was only a boxed salad sandwich to begin with, hence the sent of flatuence in the air.
I should qualify that he needs to wake up and smell the coffee instead of bloating on all that tea bagged water
That's a Kpail question. Presumably a lot were sold at a $3-$5 SP expectation earlier this year but when SP couldn't even muster up a proxy rally looks like they will expire worthless again. No surprise here.
I still think there 's something to the drug, it's the company and SP gaming by the likes of Joko and chipster that reinforced my decision to sell earlier. Been doing pretty good invested elsewhere. Hope to recover my Gern losses soon.. This still may see some traction but not quite yet.
Maybe he's finally sobered up enough to get down to do some serious govt. business...lesser miracles have happened bfr.
Jaded Joko and his transgender side kick Joan de fume are about the only dreamers left, but as we all have figured out their handles are merely ploys of the hedgefund working the 3 floor elevator at Gern
I always liked sure shot bets based on a hunch.
That's a lot to ask of IMBark where primary targets are spleen size reduction and secondary interim data won't be discussed.till perhaps later this year during an interim review. Read the abstract for the poster presentation under ASCO. "An interim review for safety, early efficacy and dosing is planned for after 20 initial points have been randomized in each arm for 12 weeks" doesn't sound like the "meat" of it will happen till sometime later during a secondary data review.
As this MM 163L trial had just been completed in April 13 do you think any trial findings were worthy of an ASCO presentation?
I though maybe Joko was kicked out of their conference due to unabridged pumping.
As to the IMbark data end points (reduced liver size) may still take time to confirm by Janssen. If patient survivability is improved through increased CR's & PR's as demo'd in the Mayo trial, they are not trial end points so perhaps this observation may not be under the Janssen shroud of darkness.
Yup, l couldn't bare to see another bear raid in my pantry. 2 years of this #$%$ has left me with bare cupboards.
How's that Need more ham upgrade working out for you Joko?
But then again he could take a year to book the payment like with the upfront payment from J&J. He's getting paid $1.3 mil to be a lackey for Janssen ultimate goal. Good compensation when you can get it.